Singapore Paincare Holdings Issues Monthly Update on Creditors’ Voluntary Winding-Up of Subsidiary
Key Points from the Latest Update
- Ongoing Winding-Up of Subsidiary: Singapore Paincare Holdings Limited (“the Company”) has provided its latest monthly update regarding the creditors’ voluntary winding-up of its 51% owned subsidiary, Dermatology & Laser Specialist Clinic Pte. Ltd. (“DLS”).
- No New Developments: The Company confirmed that, since the last update in April 2026, there have been no material developments regarding the winding-up process of DLS.
- Regular Disclosures: The Company reiterated its commitment to provide monthly updates and to make further announcements should there be any material developments related to the winding-up, in compliance with Catalist Rule 704(22).
Potentially Price-Sensitive Details for Shareholders
- Winding-Up of Subsidiary: The ongoing voluntary winding-up of a majority-owned subsidiary remains a significant event. While there are currently no new updates, the status of DLS may impact group financials and investor sentiment if future material developments arise.
- Shareholder Caution Advised: The Company specifically advises shareholders to exercise caution when dealing in its securities, given the uncertainty around the winding-up process and its potential impacts.
- Consultation Recommended: Shareholders are urged to consult their professional advisers (stockbrokers, solicitors, accountants, etc.) should they have any doubts regarding their investments.
Additional Details
- Board and Management: The update is issued by Executive Chairman and CEO, Lee Mun Kam Bernard, on 26 May 2026.
- Compliance and Oversight: The Company’s sponsor, Novus Corporate Finance Pte. Ltd., has reviewed the announcement. However, the Singapore Exchange Securities Trading Limited has not examined or approved the announcement and assumes no responsibility for its content.
- Contact Information: The point of contact for sponsor-related queries is Mr. Pong Chen Yih, COO of Novus Corporate Finance, available at their Suntec Tower 1 office in Singapore.
What Should Shareholders Do?
- Monitor Announcements: Investors are encouraged to closely monitor the Company’s monthly updates and any further announcements, as future developments regarding the subsidiary’s winding-up could affect the Company’s share value.
- Act With Caution: In light of the ongoing situation and lack of new information, shareholders are advised not to make hasty decisions regarding their holdings until more material information is released.
Disclaimer
This article is a summary of public disclosures by Singapore Paincare Holdings Limited. It does not constitute investment advice. Investors should consult their financial advisers before making any investment decisions. The Singapore Exchange Securities Trading Limited has not reviewed or approved this content.
新加坡痛症医疗控股发布子公司债权人自愿清盘的月度进展公告
报告重点
- 子公司清盘进程持续： 新加坡痛症医疗控股有限公司（“公司”）发布了关于其持股51%的子公司Dermatology & Laser Specialist Clinic Pte. Ltd.（“DLS”）债权人自愿清盘的最新月度进展。
- 无新进展： 公司确认自2026年4月以来，关于DLS清盘过程没有新的重大进展。
- 定期披露承诺： 公司重申，将继续每月更新，并在有任何重大进展时按照Catalist Rule 704(22)发布进一步公告。
对股东可能重要且影响股价的事项
- 子公司清盘事项： 子公司的持续自愿清盘是一个重大事件。尽管目前没有新动态，但DLS的状况若有新进展，未来可能影响集团财务表现与投资者情绪。
- 建议股东谨慎操作： 鉴于清盘进程的不确定性及其潜在影响，公司特别提醒股东在买卖公司股票时要谨慎。
- 建议咨询专业人士： 如有疑问，股东应咨询其证券经纪人、律师、会计师等专业顾问。
更多细节
- 董事会管理层： 此次公告由执行主席兼首席执行官Lee Mun Kam Bernard于2026年5月26日发布。
- 合规及监督： 公司主办顾问Novus Corporate Finance Pte. Ltd.已审核此公告，但新加坡证券交易所有限公司（SGX-ST）未审查或批准该公告内容，并不对其内容负责。
- 联系方式： 主办顾问联系人为Novus Corporate Finance首席运营官Pong Chen Yih先生，其办公地址为新达城第一大厦04-02室。
股东应注意什么？
- 密切关注后续公告： 投资者应密切关注公司的月度更新及任何进一步公告，因子公司清盘若有新进展，可能影响公司股票价值。
- 谨慎操作： 鉴于目前无新信息，建议股东在未有更多重大消息前，勿贸然操作持股。
免责声明
本文为新加坡痛症医疗控股有限公司公开信息的整理摘要，不构成投资建议。投资者在做出投资决策前应咨询专业财务顾问。新加坡证券交易所有限公司未审查或批准本内容。
